

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFÉ	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A5	2002/0110841	08/15/02	Kufe	435	7.23	12/26/01
	A6	2004/0166543	08/26/04	Kufe	435	7.23	12/11/03
	A7	2004/0209832	10/21/04	McSwiggen	514	44	09/23/03
	A8	2005/0042209	02/24/05	Kufe <i>et al.</i>	424	93.21	02/13/04
	A9	2005/0053606	03/10/05	Kufe <i>et al.</i>	424	155.1	09/11/01
	A10	2008/0090770	04/17/08	Belmares <i>et al.</i>	514	018	10/11/05
	A11	4,497,796	02/05/85	Salser <i>et al.</i>	514	44	12/08/82
	A12	4,675,382	06/23/87	Murphy	260	112	11/06/85
	A13	4,740,461	10/15/96	Kufe <i>et al.</i>	435	69.1	12/24/83
	A14	4,894,227	01/16/90	Stevens <i>et al.</i>	424	085.200	05/29/87
	A15	4,963,484	10/16/90	Kufe	435	069.300	01/29/88
	A16	5,053,489	10/01/91	Kufe	530	350	01/27/89
	A17	5,080,898	01/14/92	Murphy	424	94.1	02/21/89
	A18	5,506,343	04/09/96	Kufe	530	387.7	10/25/94
	A19	5,530,101	06/25/96	Queen <i>et al.</i>	530	387.3	12/19/90
	A20	5,565,334	10/17/94	Kufe <i>et al.</i>	435	69.1	10/17/94
	A21	5,612,895	03/18/97	Balaji <i>et al.</i>	702	19	04/21/95
	A22	5,776,427	07/07/98	Thorpe <i>et al.</i>	424	1.49	06/01/95
	A23	5,801,154	09/01/98	Baracchini <i>et al.</i>	514	44	04/08/97
	A24	5,861,381	01/19/99	Chambon <i>et al.</i>	514	44	06/07/95
	A25	5,998,148	12/07/99	Bennett <i>et al.</i>	435	6	04/08/99
	A26	6,004,746	12/21/99	Brent <i>et al.</i>	435	6	07/20/95
	A27	6,020,363	02/01/00	Hirano <i>et al.</i>	514	456	12/17/98

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER. INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2-3	Other Art See Page 3-22	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A28	6,054,438	04/25/00	Taylor-Papadimitiou <i>et al.</i>	514	44	06/01/95
	A29	6,074,841	06/13/00	Gearing <i>et al.</i>	435	69.1	11/19/96
	A30	6,222,020	04/24/01	Taylor-Papadimitiou <i>et al.</i>	530	395	06/01/95
	A31	6,589,921	07/08/03	Herrmann <i>et al.</i>	514	456	02/27/01
	A32	6,716,627	08/07/03	Dobie <i>et al.</i>	514	44	12/20/01
	A33	6,716,627	04/06/04	Dobie	435	375	12/20/01
	A34	60/308,307	07/27/01	Kufe			07/27/01
	A35	60/502,111	09/11/03	Jecminek <i>et al.</i>			09/11/03

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B6	EP 1103623	07/01/98	Europe	English
	B7	WO 00/34468	06/15/00	WIPO	English
	B8	WO 00/77031	12/21/00	WIPO	English
	B9	WO 01/12217	02/22/01	WIPO	English
	B10	WO 01/18035	03/15/01	WIPO	English
	B11	WO 02/058450	08/01/02	WIPO	English
	B12	WO 02/22685	03/21/02	WIPO	English
	B13	WO 02/31512	04/18/02	WIPO	English
	B14	WO 03/014303	02/20/03	WIPO	English
	B15	WO 2004/092339	10/28/04	WIPO	English
	B16	WO 91/09867	07/11/99	WIPO	English
	B17	WO 93/20841	10/28/93	WIPO	English

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B18	WO 99/23114	05/14/99	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C31	Abe <i>et al.</i> , "Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells," <i>Cancer Res.</i> , 44:4574-4577, 1984.
	C32	Adams and Cory, "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> , 281:1322-1326, 1998.
	C33	Agrawal and Kandimalla, "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Medicine Today</i> , 6:72-81, 2000.
	C34	Akagi <i>et al.</i> , "CA19-9 epitope a possible marker for MUC-1/Y protein," <i>Int. J. Oncol.</i> , 18:1085-1091, 2001.
	C35	Apostolopoulos <i>et al.</i> , "Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein," <i>British J. Cancer.</i> , 67:713-720, 1993.
	C36	Arklie <i>et al.</i> , "Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers," <i>Int. J. Cancer</i> , 28:23-29, 1981.
	C37	Ashkenazi and Dixit, "Apoptosis control by death and decoy receptors," <i>Curr. Opin. Cell Biol.</i> , 11:255-260, 1999.
	C38	Ashkenazi and Dixit, "Death Receptors: Signaling and Modulation," <i>Science</i> , 281:1305-1308, 1998.
	C39	Ashkenazi <i>et al.</i> , "Safety and antitumor activity of recombinant soluble Apo2 ligand," <i>J. Clin. Invest.</i> , 104:155-162, 1999.
	C40	Banerjee, "Omega amino acids in peptide design: incorporation into helices," <i>Biopolymers</i> , 39:769-77, 1996.
	C41	Barry and Sharkey, "Observer reproducibility during computer-assisted planimetric measurements of nuclear features," <i>Hum. Pathol.</i> , 16:225-7, 1985.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)	Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's	Applicant: Surender KHARBANDA	
INFORMATION DISCLOSURE STATEMENT	Donald W. KUFE	
(Use several sheets if necessary)	Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C42	Barry <i>et al.</i> , "Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia," <i>Biochemical Pharmacology</i> , 40:2353-2362, 1990.
	C43	Baruch <i>et al.</i> , "The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein," <i>Cancer Res.</i> , 59:1552-1561, 1999.
	C44	Bass, "The short answer," <i>Nature</i> , 411:428-429, 2001.
	C45	Batra <i>et al.</i> , "Transfection of the human MUC1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: integration, expression and ultrastructural changes," <i>J. Cell Science</i> , 100:841-849, 1991.
	C46	Bellgrau <i>et al.</i> , "A role for CD95 ligand in preventing graft rejection," <i>Nature</i> , 377:630-632, 1995.
	C47	Berger <i>et al.</i> , "Respiratory carcinoma cell lines: MUC genes and glycoconjugates," <i>American Journal of Respiratory Cell and Molecular Biology</i> , 20:500-510, 1999.
	C48	Bergeron <i>et al.</i> , "MAUB is a new mucin antigen associated with bladder cancer," <i>J. Biol. Chem.</i> , 271:6933-6940, 1996.
	C49	Beusen <i>et al.</i> , "Conformational mimicry: synthesis and solution conformation of a cyclic somatostatin hexapeptide containing a tetrazole cis amide bond surrogate," <i>Biopolymers</i> , 36:181-200, 1995.
	C50	Bird <i>et al.</i> , "Single-chain antigen-binding proteins," <i>Science</i> , 242:423-6, 1988.
	C51	Bitko <i>et al.</i> , "Inhibition of respiratory viruses by nasally administered siRNA," <i>Nature Med.</i> , 11:50-55, 2005.
	C52	Bodmer <i>et al.</i> , "Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL," <i>J. Biol. Chem.</i> , 275:20632-20637, 2000.
	C53	Boldin <i>et al.</i> , "Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death," <i>Cell</i> , 85:803-815, 1996
	C54	Brossart <i>et al.</i> , "Identification of HLA-A2-restricted T-cell epitopes derived from MUC1 tumor antigen for broadly applicable vaccine therapies," <i>Blood</i> , 93:4309-4317, 1999.
	C55	Brunner <i>et al.</i> , " <i>pangolin</i> encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in <i>Drosophila</i> ," <i>Nature</i> , 385:829-33, 1997.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C56	Bumcrot <i>et al.</i> , "RNAi therapeutics: a potential new class of pharmaceutical drugs," <i>Nature Chemical Biology</i> , 2:711-719, 2006.
	C57	Bunz, "Cell death and cancer therapy," <i>Curr. Opin. Pharmacol.</i> , 1:337-341, 2001.
	C58	Burchell <i>et al.</i> , "A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes," <i>Int. J. Cancer</i> , 44:691-696, 1989.
	C59	Burchell <i>et al.</i> , "Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin," <i>Cancer Res.</i> , 47:5476-5482, 1987.
	C60	Burns and El-Deiry, "Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach," <i>J. Biol. Chem.</i> , 276:37879-37886, 2001.
	C61	Burton <i>et al.</i> , "Epithelial mucin (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma," <i>Clin. Can. Res.</i> , 5:3065s-3072s, 1999.
	C62	Busfield <i>et al.</i> , "Characterization of a neuregulin-related gene, <i>Don-1</i> , that is highly expressed in restricted regions of the cerebellum and hippocampus," <i>Mol. Cell. Biol.</i> , 17:4007-4014, 1997.
	C63	Cawley <i>et al.</i> , "Epidermal growth factor-toxin A chain conjugates: EGF-Ricin A is a potent toxin while EGF-Diphtheria fragment A is nontoxic," <i>Cell</i> , 22:563-570, 1980.
	C64	Chang <i>et al.</i> , "Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide conjugate," <i>J. Biol. Chem.</i> , 252:1515-1522, 1977.
	C65	Chang <i>et al.</i> , "Ligands for ErbB-family receptors encoded by a neuregulin-like gene," <i>Nature</i> , 387:509-512, 1997.
	C66	Chaudhary <i>et al.</i> , "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 87:1066-70, 1990.
	C67	Chaudhary <i>et al.</i> , "Activity of a recombinant fusion protein between transforming growth factor type alpha and <i>Pseudomonas</i> toxin," <i>Proc. Natl. Acad. Sci. USA</i> , 84:4538-4542, 1987.
	C68	Ciborowski <i>et al.</i> , "Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes," <i>Tumor Biology</i> , 19:147-151, 1998.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's		Applicant: Surender KHARBANDA	
INFORMATION DISCLOSURE STATEMENT		Donald W. KUFE	
(Use several sheets if necessary)		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C69	Console <i>et al.</i> , "Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans," <i>J. Biol. Chem.</i> , 278 :35109-14, 2003.
	C70	Creagan <i>et al.</i> , "Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma," <i>J. Clin. Oncol.</i> , 17:1884-1890, 1999.
	C71	Croghan <i>et al.</i> , "Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22," <i>Cancer Res.</i> , 43:4980-4988, 1983.
	C72	Daniel and Reynolds, "The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor," <i>Mol. Cell. Biol.</i> , 19:3614-23, 1999.
	C73	Datta <i>et al.</i> , "Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation," <i>Cell Growth Differ.</i> 6:363-370, 1995.
	C74	Dawson <i>et al.</i> , "Synthesis of proteins by native chemical ligation," <i>Science</i> , 266:776-779, 1994.
	C75	Deng <i>et al.</i> , "TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO," <i>Genes Dev.</i> , 16:33-45, 2002.
	C76	Derossi <i>et al.</i> , "Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent," <i>J Biol. Chem.</i> , 271:18188-93, 1996.
	C77	Derossi <i>et al.</i> , "The third helix of the Antennapedia homeodomain translocates through biological membranes," <i>J Biol. Chem.</i> , 269:10444-50, 1994.
	C78	Deveraux and Reed, "IAP family proteins--suppressors of apoptosis," <i>Genes Dev.</i> , 13:239-52, 1999.
	C79	Dillman, "Antibodies as cytotoxic therapy," <i>J. Clin. Oncology</i> , 12:1497-1515, 1994.
	C80	Dorn <i>et al.</i> , "Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2," <i>Anticancer Research</i> , 24:821-826, 2004.
	C81	Doyle, "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ," <i>Cell</i> , 85:1067-76, 1996.
	C82	Drucker <i>et al.</i> , "Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures," <i>Anticancer Research</i> , 23:1549-1554, 2003.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C83	Du <i>et al.</i> , "Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition," <i>Cell</i> , 102:33-42, 2000.
	C84	Dykxhoorn <i>et al.</i> , "The silent treatment: siRNAs as small molecule drugs," <i>Gene Therapy</i> , 13:541-552, 2006.
	C85	Elbashir <i>et al.</i> , "Functional anatomy of siRNAs for mediating efficient RNAi in <i>Drosophila melanogaster</i> embryo lysate," <i>EMBO Journal</i> , 20:6877-6888, 2001.
	C86	Elbashir <i>et al.</i> , "RNA interference is mediated by 21- and 22-nucleotide RNAs," <i>Genes and Development</i> , 15:188-200, 2001.
	C87	Elliot and O'Hare, "Inter cellular trafficking and protein delivery by a herpesvirus structural protein," <i>Cell</i> , 88:223-33, 1997.
	C88	Elmqvist <i>et al.</i> , "VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions," <i>Exp. Cell Res.</i> , 269:237-44, 2001.
	C89	Emoto <i>et al.</i> , "Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells," <i>EMBO J.</i> , 14:6148-6156, 1995.
	C90	Faivre <i>et al.</i> , "Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxalipatin in human cancer cell lines," <i>Cancer Chemother. Pharmacol.</i> , 44:117-123, 1999.
	C91	Feigl, "2,8-Dimethyl-4-(carboxymethyl)-6-(aminomethyl)phenoxathiin S-Dioxide: An Organic Substitute for the beta-Turn in Peptides," <i>J. Amer. Chem. Soc.</i> , 108:181-2, 1986.
	C92	Finn <i>et al.</i> , "MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines," <i>Immunol. Rev.</i> , 145:61-89, 1995.
	C93	Fontenot <i>et al.</i> , "Biophysical characterization of one-, two-, and three-tandem repeats of human musin (muc-1) protein core," <i>Cancer Research</i> , 53:5386-5394, 1993.
	C94	Frankel and Pabo, "Cellular uptake of the tat protein from human immunodeficiency virus," <i>Cell</i> , 55:1189-93, 1989.
	C95	French and Tschopp, "Inhibition of Death Receptor Signaling by FLICE-inhibitory Protein as a Mechanism for Immune Escape of Tumors," <i>J. Exp. Med.</i> , 190:891-893, 1999.
	C96	Futaki <i>et al.</i> , "Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery," <i>J. Biol. Chem.</i> , 276 :5836-40, 2001.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER. INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C97	Gay <i>et al.</i> , "Selective GRB2 SH2 inhibitors as anti-RAS therapy," <i>Int. J. Cancer</i> , 83:235-241, 1999.
	C98	Geisbert <i>et al.</i> , "Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge is Conferred by RNA Interference," <i>J. Infectious Diseases</i> , 193:1650-1657, 2006.
	C99	Gendler <i>et al.</i> , "Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin," <i>J. Biol. Chem.</i> , 265:15286-15293, 1990.
	C100	George, D.G. <i>et al.</i> , "Chapter 12. Current Methods in Sequence Comparison and Analysis," in: <i>Macromolecular Sequencing and Synthesis. Selected Methods and Applications</i> , Alan R. Liss, Inc., pp. 127-149 (1988).
	C101	Gopalakrishnan <i>et al.</i> , "Application of Micro Arrayed Compound Screening (microARCS) to identify inhibitors of caspase-3," <i>J. Biomol. Screen.</i> , 7:317-23, 2002.
	C102	Green and Loewenstein, "Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein," <i>Cell</i> , 55:1179-88, 1989.
	C103	Griffith <i>et al.</i> , "CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance," <i>Immunity</i> , 5:7-16, 1996.
	C104	Gross <i>et al.</i> , "Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death," <i>J. Biol. Chem.</i> , 274:1156-1163, 1999.
	C105	Grzelinski <i>et al.</i> , "RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts," <i>Human Gene Therapy</i> , 17:751-766, 2006.
	C106	Gutierrez <i>et al.</i> , "Gene therapy for cancer," <i>The Lancet</i> , 339:715-721, 1992.
	C107	Haim <i>et al.</i> , "Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in Non-Hodgkin lymphoma," <i>Am. J. Clin. Oncol.</i> , 22:47-50, 1999.
	C108	Hammond <i>et al.</i> , "Post-transcriptional gene silencing by double-stranded RNA," <i>Nature Genetics</i> , 2:110-119, 2001.
	C109	Hanson <i>et al.</i> , "MUC1 expression in primary breast cancer: the effect of tamoxifen treatment," <i>Breast Cancer Research and Treatment</i> , 67:215-222, 2001.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C110	Harborth <i>et al.</i> , "Identification of essential genes in cultured mammalian cells using small interfering RNAs," <i>J. Cell Science</i> , 114:4557-4565, 2001.
	C111	Harlow and Lane, "Antibodies, A Lab Manual," Cold Spring Harbor, 1988.
	C112	Harris <i>et al.</i> , "Therapeutic antibodies – the coming of age," <i>Tibtech</i> , 11:12-44, 1993.
	C113	Harrison, "Peptide-surface association: the case of PDZ and PTB domains," <i>Cell</i> , 86:341-343, 1996.
	C114	Hartman <i>et al.</i> , "MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer," <i>Int. J. Cancer</i> , 82:256-267, 1999.
	C115	Hayes <i>et al.</i> , "Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer," <i>J. Clin. Oncol.</i> , 4:1542-1550, 1986.
	C116	Hayes <i>et al.</i> , "Genetically determined polymorphism of the circulating human breast cancer-associated DF3 antigen," <i>Blood</i> , 71:436-440, 1998.
	C117	Herr and Debatin, "Cellular stress response and apoptosis in cancer therapy," <i>Blood</i> , 98:2603-2614, 2001.
	C118	Higashiyama <i>et al.</i> , "A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4," <i>J. Biochem.</i> , 122:675-680, 1997.
	C119	Higgins, "Comparison of the solution conformations of a human immunodeficiency virus peptidomimetic and its retro-inverso isomer using 1H NMR spectroscopy," <i>J. Pept. Res.</i> , 50:421-35, 1997.
	C120	Hilkens <i>et al.</i> , "Biosynthesis of MAM-6, an epithelial sialomucin," <i>J. Biol. Chem.</i> , 263:4215-4222, 1988.
	C121	Hilkens <i>et al.</i> , "Complexity of MAM-6, an epithelial sialomucin associated with carcinomas," <i>Cancer Res.</i> , 49:786-793, 1989.
	C122	Hilkens <i>et al.</i> , "Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors," <i>Int. J. Cancer</i> , 34:197-206, 1984.
	C123	Hird <i>et al.</i> , "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody," <i>Br. J. Cancer</i> , 68:403-406, 1993.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2-3	Other Art See Page 3-22	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C124	Hopp, "Protein surface analysis. Methods for identifying antigenic determinants and other interaction sites," <i>J. Immunol. Methods</i> , 88:1-18, 1986.
	C125	Houghton <i>et al.</i> , "Monoclonal antibodies: potential applications to the treatment of cancer," <i>Seminars in Oncology</i> , 13:165-179, 1986.
	C126	Hruby <i>et al.</i> , "Design of peptides, proteins, and peptidomimetics in chi space," <i>Biopolymers</i> , 43:219-66, 1997.
	C127	Hug <i>et al.</i> , "Liposomes for the transformation of eukaryotic cells," <i>Biochem. Biophys. Acta.</i> , 1097:1-17, 1991.
	C128	Hull <i>et al.</i> , "Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinomas cell line," <i>Cancer Commun.</i> , 1:261-267, 1989.
	C129	Hunt and Evans, "Till Death Us Do Part," <i>Science</i> , 293:1784-1785, 2001.
	C130	Huston <i>et al.</i> , "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci U.S.A.</i> , 85:5879-83, 1988.
	C131	Hymowitz <i>et al.</i> , "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5," <i>Mol. Cell.</i> , 4:563-571, 1999.
	C132	Ikedo <i>et al.</i> , "Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid," <i>Molecular Cancer Therapeutics</i> , 3:39-45, 2004.
	C133	Irmeler <i>et al.</i> , "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> , 388:190-195, 1997.
	C134	Itzkowitz <i>et al.</i> , "Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients," <i>Cancer</i> , 66:1960-6, 1990.
	C135	Jaattela <i>et al.</i> , "Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells," <i>Oncogene</i> , 10:2297-2305, 1995.
	C136	Jawhari <i>et al.</i> , "Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma," <i>J. Pathol.</i> 189:180-5, 1999.
	C137	Jen <i>et al.</i> , "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies," <i>Stem Cells</i> , 18:307-319, 2000.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)	Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Sunder Kharbanda Donald W. KuFe	
	Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2-3	Other Art See Page 3-22

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C138	Jin <i>et al.</i> , "CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals," <i>Genes Dev.</i> , 17:359-67, 2003.
	C139	Kahn <i>et al.</i> , "Nonpeptide Mimetics of beta-Turns: A Facile Oxidative Intramolecular Cycloaddition of an Azodicarbonyl System," <i>J. Amer. Chem. Soc.</i> , 110:1638-9, 1988.
	C140	Kahn, "The design and synthesis of mimetics of peptide beta-turns," <i>J. Molec. Recognition</i> , 1:75-9, 1988.
	C141	Kalofonos <i>et al.</i> , "Kinetics, quantitative analysis and radioimmunolocalisation using indium-111-HMFG1 monoclonal antibody in patients with breast cancer," <i>Cr. J. Cancer</i> , 59:939-942, 1989.
	C142	Kalofonos <i>et al.</i> , "Radioimmunoschintigraphy in patients with ovarian cancer," <i>Acta Oncologica</i> , 38:629-634, 1999.
	C143	Kam <i>et al.</i> , "MUC1 synthetic peptide inhibition of intracellular adhesion molecule-1 and MUC1 binding requires six tandem repeats," <i>Cancer Res.</i> , 58:5577-5581, 1988.
	C144	Karlsson <i>et al.</i> , "A genetic polymorphism of a human urinary mucin," <i>Ann. Hum. Genet.</i> , 47:263, 1983.
	C145	Karvinen <i>et al.</i> , "Homogeneous time-resolved fluorescence quenching assay (LANCER) for caspase-3," <i>J. Biomol. Screen.</i> , 7:223-31, 2002.
	C146	Kataoka <i>et al.</i> , "FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation," <i>J. Immunol.</i> , 161:3936-3942, 1998.
	C147	Kayagaki <i>et al.</i> , "Metalloproteinase-mediated release of human Fas ligand," <i>J. Exp. Med.</i> , 182:1777-1783, 1995.
	C148	Kemp and Stites, "A convenient preparation of derivatives of 3(s)-amino-109(r)-carboxy-1,6-diazacyclodeca-2,7-dione the diastam of L-alphagamma-diaminobutyric acid and d-glutamic acid: a beta-turn template," <i>Tet. Lett.</i> , 29:5057-60, 1988.
	C149	Kennerdell <i>et al.</i> , "Heritable gene silencing in <i>Drosophila</i> using double-stranded RNA," <i>Nature Biotechnology</i> , 17:896-898, 2000.
	C150	Kharbanda <i>et al.</i> , "Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53 tyrosine kinase with p34cdc2," <i>Cancer Res.</i> , 56:3617-3621, 1996.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunder Kharbanda Donald W. KuFe	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2-3	Other Art See Page 3-22	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C151	Kim <i>et al.</i> , "Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma," <i>Molecular Therapy</i> , 14:343-350, 2006.
	C152	Kischkel <i>et al.</i> , "Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor," <i>EMBO J.</i> , 14:5579-5588, 1995.
	C153	Kluck <i>et al.</i> , "The Release of Cytochrome c from Mitochondria: A Primary Site for BCL-2 Regulation of Apoptosis," <i>Science</i> , 275:1132-1136, 1997.
	C154	Kondo <i>et al.</i> , "Decreased MUC1 expression induces E-Cadherin-mediated cell adhesion of breast cancer cell lines," <i>Cancer Research</i> , 58:2014-2019, 1998.
	C155	Kotera <i>et al.</i> , "Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in Ser from brea, pancreatic, and colon cancer patients," <i>Cancer Research</i> , 54:2856-2860, 1994.
	C156	Kroemer and Reed, "Mitochondrial control of cell death," <i>Nat. Med.</i> , 6:513-519, 2000.
	C157	Kumar <i>et al.</i> , "Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor ST1571," <i>Mol. Pharmacol.</i> , 63:276-282, 2003.
	C158	Kuppuswamy <i>et al.</i> , "Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis," <i>Nucl. Acids Res.</i> , 17:3551-61, 1989.
	C159	Lancaster <i>et al.</i> , "Structure and expression of the human polymorphic epithelial mucin cenge: an expressed VNTR unit," <i>Biochim. Biophys. Res. Comm.</i> , 173:1019-1029, 1990.
	C160	LaVallee <i>et al.</i> , "2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway," <i>Cancer Research</i> , 63:468-475, 2003.
	C161	LeBlanc <i>et al.</i> , "Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax," <i>Nat. Med.</i> , 8:274-281, 2002.
	C162	Lewis <i>et al.</i> , "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," <i>Nature Genetics</i> , 32:107-108, 2002.
	C163	Li and KuFe, "The human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120 ^{cas} ," <i>Biochem. Biophys. Res. Commun.</i> , 281:440-443, 2001.
	C164	Li <i>et al.</i> , "Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the FAS Pathway of Apoptosis," <i>Cell</i> , 94:491-501, 1998.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C165	Li <i>et al.</i> , "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex initiates and Apoptotic Protease Cascade," <i>Cell</i> , 91:479-489, 1997.
	C166	Li <i>et al.</i> , "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7," <i>Cancer Biol. Ther.</i> , 2:187-193, 2003.
	C167	Li <i>et al.</i> , "The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-SRC and β -catenin," <i>JBC Papers in Press</i> , manuscript C100359200, August 1, 2001.
	C168	Li <i>et al.</i> , "Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque," <i>Nature Med.</i> , 11:944-951, 2005.
	C169	Ligtenberg <i>et al.</i> , "Cell associated episialin is a complex containing two proteins derived from a common precursor," <i>J. Biol. Chem.</i> , 267:6171-6177, 1992.
	C170	Lin <i>et al.</i> , "Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence," <i>J. Biol. Chem.</i> , 270:14255-8, 1995.
	C171	Liu <i>et al.</i> , "Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs," <i>Proc. Natl Acad. Sci. U.S.A.</i> , 93 :11819-24, 1996.
	C172	Liu <i>et al.</i> , "Induction of Apoptotic Program in Cell-Free Extracts: Requirement of dATP and Cyochrome c," <i>Cell</i> , 86:147-157, 1996.
	C173	Luo <i>et al.</i> , "An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons," <i>Molecular Pain</i> , 1:29, 2005.
	C174	Luo <i>et al.</i> , "Bid, A Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors," <i>Cell</i> , 94:481-490, 1998.
	C175	Makimura <i>et al.</i> , "Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake," <i>BMC Neuroscience</i> , 3:18, 2002.
	C176	Maraveyas <i>et al.</i> , "Pharmacokinetics and toxicity of an Yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer," <i>Cancer</i> , 73:1067-1075, 1994.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's		Applicant: Sunder Kharbanda Donald W. KuFe	
INFORMATION DISCLOSURE STATEMENT		Filing Date: December 13, 2006	Group: 1643
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C177	Maraveyas <i>et al.</i> , "Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma," <i>Cancer Research</i> , 55:1060-1069, 1995.
	C178	Mariani <i>et al.</i> , "Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases," <i>Eur. J. Immunol.</i> , 25:2303-2307, 1995.
	C179	Marsters <i>et al.</i> , "A novel receptor for Apo2L/TRAIL contains a truncated death domain," <i>Curr. Biol.</i> , 7:1003-1006, 1997.
	C180	Martinez <i>et al.</i> , "Single-stranded antisense siRNAs guide target RNA cleavage in RNAi," <i>Cell</i> , 110:563-574, 2002.
	C181	Martins, "The serine protease Omi/HtrA2: a second mammalian protein with a Reaper-like function," <i>Cell Death Diff.</i> , 9:699-701, 2002.
	C182	McGrath <i>et al.</i> , "The Yeast STE6 gene encodes a homologue of the mammalian multidrug resistance P-Glycoprotein," <i>Nature.</i> , 340:400, 1989.
	C183	McGuckin <i>et al.</i> , "Prognostic significance of MUC1 epithelial mucin expression in breast cancer," <i>Human Pathology</i> , 26:432-439, 1995.
	C184	Melani <i>et al.</i> , "Inhibition of proliferation by c-myc antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myc," <i>Cancer Research</i> , 51:2897-2901, 1991.
	C185	Mi <i>et al.</i> , "Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo," <i>Mol. Ther.</i> , 2:339-47, 2000.
	C186	Milik <i>et al.</i> , "Lung lymphocyte elimination by apoptosis in the murine response to intratracheal particulate antigen," <i>J. Clin. Invest.</i> , 99:1082-1091, 1997.
	C187	Minakuchi <i>et al.</i> , "Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo," <i>Nucleic Acids Research</i> , 32:e109, 2004.
	C188	Molenaar <i>et al.</i> , "XTCF-3 transcription factor mediates beta-catenin-induced axis formation in <i>Xenopus</i> embryos," <i>Cell</i> , 86:391-9, 1996.
	C189	Morris <i>et al.</i> , "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," <i>Nucleic Acid Res.</i> , 25:2730-6, 1997.
	C190	Muzio <i>et al.</i> , "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (fas/APO-1) Death-Inducing Signaling Complex," <i>Cell</i> , 85:817-827, 1996.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C191	Nagai and Sato, "Synthesis of a bicyclic dipeptide with the shape of beta-turn central part," <i>Tet. Lett.</i> , 26:647-50, 1985.
	C192	Nagata, "Apoptosis by Death Factor," <i>Cell</i> , 88:355-365, 1997.
	C193	Nakamura <i>et al.</i> , "RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis," <i>Molecular Vision</i> , 10:703-711, 2004.
	C194	Nakashima <i>et al.</i> , "Inhibition of angiogenesis by a new isocoumarin, NM-3," <i>J. Antibiotics</i> , 52:426-428, 1999.
	C195	Neyfakh <i>et al.</i> , "Efflux-mediated multidrug resistance in bacillus subtilis: similarities and dissimilarities with the mammalian system," <i>Proc. Natl. Acad. Sci. USA</i> , 88:4781-4785, 1991.
	C196	Nicholson <i>et al.</i> , "Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis," <i>Oncology Reports</i> 5:223-226, 1998.
	C197	Niethammer <i>et al.</i> , "CRIPT, a novel postsynaptic protein that binds to the third PDZ domain of PSD-95/SAP90," <i>Neuron</i> , 20:693-707, 1989.
	C198	Niu <i>et al.</i> , "Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo," <i>Int. J. Gynecol. Cancer</i> , 16:743-751, 2006.
	C199	Novak and Dedhar, "Signaling through beta-catenin and Lef/Tcf," <i>Cell Mol. Life Sci.</i> , 523-37, 1999.
	C200	Oehlke <i>et al.</i> , "Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically," <i>Biochim. Biophys. Acta.</i> , 1414: 127-39, 1998.
	C201	Okazaki <i>et al.</i> , "Downregulation of gastric mucin gene expression and its biosynthesis by dexamethasone in the human," <i>J. Clin. Gastroenterol.</i> , 27(suppl. 1):S91-S92, 1998.
	C202	Opalinska <i>et al.</i> , "Nucleic-acid therapeutics: basic principles and recent applications," <i>Nature Reviews Drug Discovery</i> , 1:503-514, 2002.
	C203	Orkin Report & Recommendations of The Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.
	C204	Padrón <i>et al.</i> , "Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures," <i>Anti-Cancer Drugs</i> , 10:445-452, 1999.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C205	Palliser <i>et al.</i> , "An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection," <i>Nature</i> , 439:89-94, 2006.
	C206	Pan <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> , 277:815-818, 1997.
	C207	Pan <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> , 276:111-113, 1997.
	C208	Pandey <i>et al.</i> , "Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein," <i>Cancer Res.</i> , 55:4000-4003, 1995.
	C209	Parrish <i>et al.</i> , "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference," <i>Molecular Cell</i> , 8:1077-1087, 2000.
	C210	Paszkiwicz-Gadek <i>et al.</i> , "Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen," <i>Gynecol. Endocrinol.</i> , 17:37-44, 2003.
	C211	Pavlovic <i>et al.</i> , "Targeting of non-small cell lung cancer using HMFG1- ^{99m} Tc monoclonal antibodies," <i>Med Pregl.</i> , 46 Suppl 1:26-28, 1993
	C212	Perey <i>et al.</i> , "Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen," <i>Cancer Research</i> , 52:2563-2568, 1992.
	C213	Perez <i>et al.</i> , "Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide," <i>J. Cell. Sci.</i> , 102:717-22, 1992.
	C214	Pescarolo <i>et al.</i> , "A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems," <i>FASEB J.</i> , 15:31-3, 2001.
	C215	Pitti <i>et al.</i> , "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family," <i>J. Biol. Chem.</i> , 271:12687-12690, 1996.
	C216	Pooga <i>et al.</i> , "Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo," <i>Nature Biotech.</i> , 16 :857-61, 1998.
	C217	Porowska <i>et al.</i> , "MUC1 expression in human breast cancer cells is altered by the factors affecting cell proliferation," <i>Neoplasma</i> , 49:104-109, 2002.
	C218	Price <i>et al.</i> , "Immunological and structural features of the protein core of human polymorphic epithelial mucin," <i>Molecular Immunology</i> , 27:795-802, 1990.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2-3	Other Art See Page 3-22	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C219	Price <i>et al.</i> , "Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin," San Diego, California, November 17-23, 1996, <i>Tumor Biol.</i> , 19:sup. 1:1-20, 1998.
	C220	Rewcastle <i>et al.</i> , "Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-Bromophenyl) amino]-6-(methylamino)-pyridine [3,4- <i>d</i>] pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors," <i>J. Med. Chem.</i> , 41:742-751, 1998.
	C221	Reddish <i>et al.</i> , "Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy," <i>Cancer Immunol. Immunother.</i> , 42:303-9, 1996.
	C222	Reich <i>et al.</i> , "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , 9:210-216, 2003.
	C223	Reynolds <i>et al.</i> , "Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes," <i>Mol. Cell. Biol.</i> , 14:8333-42, 1994.
	C224	Reynolds <i>et al.</i> , "Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene," <i>Mol. Cell. Biol.</i> , 9:629-38, 1989.
	C225	Rondinone, "Therapeutic potential of rai in metabolic diseases," <i>BioTechniques</i> , 40:S31-S36, 2006.
	C226	Rousselle <i>et al.</i> , "New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy," <i>Mol. Pharmacol.</i> , 57:679-86, 2000.
	C227	Ruben <i>et al.</i> , "Structural and functional characterization of human immunodeficiency virus tat protein," <i>J. Virol.</i> , 63(1):1-8, 1989.
	C228	Sato <i>et al.</i> , "FAP-1: A Protein Tyrosine Phosphatase That Associates with Fas," <i>Science</i> , 268:411-415, 1995.
	C229	Scaffidi <i>et al.</i> , "Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells," <i>J. Biol. Chem.</i> , 274:22532-22538, 1999.
	C230	Schiffelers <i>et al.</i> , "Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle," <i>Nucleic Acids Research</i> , 32:e149, 2004.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2-3	Other Art See Page 3-22	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C231	Schneider <i>et al.</i> , "Mutagenesis and selection of PDZ domains that bind new protein targets," <i>Nat. Biotech.</i> , 17:170-5, 1998.
	C232	Schultz <i>et al.</i> , "Specific interactions between the syntrophin PDZ domain and voltage-gated sodium channels," <i>Nat. Struct. Biol.</i> , 5:19-24, 1998.
	C233	Schumacher <i>et al.</i> , "Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies," <i>Cancer Research</i> , 61:3712-3717, 2001.
	C234	Sekine <i>et al.</i> , "Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas," <i>J. Immunol.</i> , 135:3610-3615, 1985.
	C235	Shen <i>et al.</i> , "Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1," <i>Gene Therapy</i> , 13:225-234, 2006.
	C236	Sherman <i>et al.</i> , "Ionizing radiation regulates expression of the c-jun protooncogene," <i>Proc. Natl. Acad. Sci. USA</i> , 87:5663-5666, 1990.
	C237	Shimazui <i>et al.</i> , "Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors," <i>Cancer Res.</i> , 56:4154-8, 1996.
	C238	Sloane <i>et al.</i> , "Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology," <i>Cancer</i> , 47:1786-1795, 1981.
	C239	Smith and Waterman, "Comparison of Biosequences," <i>Adv. Appl. Math.</i> , 2:482-9, 1981.
	C240	Smith, "Design, Synthesis, and Crystal Structure of a Pyrrolinon-Based Peptidomimetic Possessing the Conformation of a beta-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes," <i>J. Amer. Chem. Soc.</i> , 114:10672-4, 1992.
	C241	Snyder <i>et al.</i> , "Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating peptide," <i>PLoS Biology</i> , 2:186-93, 2004.
	C242	Songyang <i>et al.</i> , "Recognition of unique carboxyl-terminal motifs by distinct PDZ domains," <i>Science</i> , 275:73-7, 1997.
	C243	Soomets <i>et al.</i> , "Deletion analogues of transportin," <i>Biochim. Biophys. Acta</i> , 1467:165-176, 2000.
	C244	Soutschek <i>et al.</i> , "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," <i>Nature</i> , 432:173-178, 2004.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C245	Spatola, "A Peptide Backbone Modifications," In: Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, 7:267-357, Marcell Dekker, NY, 1983.
	C246	Srinivasan <i>et al.</i> , "Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells," <i>J. Biol. Chem.</i> , 273:4523-4529, 1998.
	C247	Srinivasula <i>et al.</i> , "Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization," <i>Mol. Cell.</i> , 1:949-957, 1998.
	C248	Stennicke <i>et al.</i> , "Pro-caspase-3 is a major physiologic target of caspase-8," <i>J. Biol. Chem.</i> , 273:27084-27090, 1998.
	C249	Strous and Decker, "Mucin-Type Glycoproteins," <i>Crit. Rev. Biochem., Mol. Biol.</i> , 27:57-92, 1992.
	C250	Struhl, "Delection mapping a eukaryotic promoter," <i>Proc. Natl. Acad. Sci. USA</i> , 78:4461-4465, 1981.
	C251	Subbarao <i>et al.</i> , "pH-dependent bilayer destabilization by an amphipathic peptide," <i>Biochemistry</i> , 26:2964-2972, 1987.
	C252	Swallow <i>et al.</i> , "The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM," <i>Nature</i> , 328:82-84, 1987.
	C253	Takei <i>et al.</i> , "A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics," <i>Cancer Research</i> , 64:3365-3370, 2004.
	C254	Takeichi, "Cadherins: a molecular family important in selective cell-cell adhesion," <i>Annu. Rev. Biochem.</i> , 59:237-52, 1990.
	C255	Taylor <i>et al.</i> , "Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination," <i>Drug Discovery Today</i> , 4:562-567, 1999.
	C256	Thakker <i>et al.</i> , "siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain," <i>Molecular Psychiatry</i> , 10:782-789, 2005.
	C257	Timmer <i>et al.</i> , "Fas receptor-mediated apoptosis: a clinical application?" <i>J. Pathol.</i> , 196:125-134, 2002.
	C258	Tondini <i>et al.</i> , "Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer," <i>Cancer Res.</i> , 48:4107-4112, 1988.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-J 449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C259	Tondini <i>et al.</i> , "Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for <i>in Vitro</i> purging of human bone marrow," <i>Cancer Research</i> , 50:1170-1175, 1990.
	C260	Topp <i>et al.</i> , "MUC-1 specific T-cells are present in multiple myeloma patients at high frequency after allogeneic transplantation but may not mediate the graft versus myeloma effect," <i>Blood</i> , 100: page Abstract No. 5191, 2002.
	C261	Torchilin and Levchenko, "TAT-liposomes: a novel intracellular drug carrier," <i>Curr. Protein Pept. Sci.</i> , 4:133-40, 2003.
	C262	Tseng <i>et al.</i> , "Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study," <i>Mol. Pharmacol.</i> , 62:864-72, 2002.
	C263	Urban-Klein <i>et al.</i> , "RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA <i>in vivo</i> ," <i>Gene Therapy</i> , 12:461-466, 2005.
	C264	van Hof <i>et al.</i> , "Biodistribution of 111Indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose," <i>Cancer Research</i> , 56:5179-5185, 1996.
	C265	Van Zonneveld <i>et al.</i> , "Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter," <i>Proc. Natl. Acad. Sci. USA</i> , 85:5525-5529, 1988.
	C266	Verhagen <i>et al.</i> , "Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins," <i>Cell</i> , 102:43-53, 2000.
	C267	Vermeer <i>et al.</i> , "Segregation of receptor and ligand regulates activation of epithelial growth factor receptor," <i>Nature</i> , 422:322-326, 2003.
	C268	Vives <i>et al.</i> , "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus," <i>J. Biol. Chem.</i> , 272:16010-7, 1997.
	C269	Vleck <i>et al.</i> , "Pseudorabies virus immediate-early gene overlaps with an oppositely oriented open reading frame: Characterization of their promoter and enhancer regions," <i>Virology</i> , 179:365,337, 1990.
	C270	Walczak <i>et al.</i> , "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> , 16:5386-5397, 1997.
	C271	Walczak <i>et al.</i> , "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand <i>in vivo</i> ," <i>Nat. Med.</i> , 5:157-163, 1999.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Surender KHARBANDA Donald W. KUFE	
		Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C272	Waldmann, "Monoclonal antibodies in diagnosis and therapy," <i>Science</i> 252:1657-1662, 1991.
	C273	Walsh <i>et al.</i> , "Heterogeneity of MUC1 expression by human breast carcinoma cell lines <i>in vivo</i> and <i>in vitro</i> ," <i>Breast Cancer Research and Treatment</i> , 58:255-266, 2000.
	C274	Wang and El-Deiry, "TRAIL and apoptosis induction by TNF-family death receptors," <i>Oncogene</i> , 24:8628-8633, 2003.
	C275	Wei <i>et al.</i> , "MUC1 oncoprotein stabilizes and activates estrogen receptor α ," <i>Molecular Cell</i> , 21:295-305, 2006.
	C276	Wender <i>et al.</i> , "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters," <i>Proc. Natl. Acad. Sci., U.S.A.</i> , 97:13003-8, 2000.
	C277	Williams <i>et al.</i> , "Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide," <i>J. Biol. Chem.</i> , 272:22349-54, 1997.
	C278	Wreschner <i>et al.</i> , "Does a novel form of the breast cancer marker protein MUC1, act as receptor molecule that modulates signal transduction," In: <i>Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment</i> , Ed. Ceriani Plenum Press, New York, pp. 17-26, 1994.
	C279	Xia <i>et al.</i> , "siRNA-mediated gene silencing <i>in vitro</i> and <i>in vivo</i> ," <i>Nature Biotechnology</i> , 20:1006-1010, 2002.
	C280	Xing <i>et al.</i> , "Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies," <i>Cancer Research</i> , 50:89-96, 1990.
	C281	Xing <i>et al.</i> , "Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions," <i>Immunology</i> , 72:304-311, 1991.
	C282	Xing <i>et al.</i> , "Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies," <i>Molecular Immunology</i> , 29:641-650, 1992.
	C283	Xing <i>et al.</i> , "Monoclonal antibodies reactive with mucin expressed in breast cancer," <i>Immunol. Cell. Biol.</i> , 67:183-195, 1989.
	C284	Xing <i>et al.</i> , "Second generation anti-MUC1 peptide monoclonal antibodies," <i>Cancer Research</i> , 52:2310-2317, 1992.
	C285	Yang <i>et al.</i> , "Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked," <i>Science</i> , 275:1129-1132, 1997.

70146462.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 (modified)	Atty. Docket No.: GENU:005US	Serial No.: 10/577,003
List of Patents and Publications for Applicant's	Applicant: Surender KHARBANDA	
INFORMATION DISCLOSURE STATEMENT	Donald W. KUFE	
(Use several sheets if necessary)	Filing Date: December 13, 2006	Group: 1643
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-22</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C286	Zimmerman <i>et al.</i> , "RNAi-mediated gene silencing in non-human primates," <i>Nature</i> , 441:111-114, 2006.
	C287	Zrihan-Licht <i>et al.</i> , "Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins: cytokine receptor-like molecules," <i>FEBS Let.</i> , 356:130-136, 1994.

70146462.1

EXAMINER: /David Blanchard/

DATE CONSIDERED: 01/16/2009

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/